RESEARCH
DPD Enzyme Pathway May Predict Immunotherapy Response in MSI-H CRCA new study identifies the dihydropyrimidine dehydrogenase (DPD) metabolic pathway as the first predictor of immune checkpoint inhibitor efficacy in MSI-H tumors, potentially helping identify patients at risk for resistance. (Journal for ImmunoTherapy of Cancer)